Connect with us

Drug Manufacturers - Specialty and Generic

Piramal Pharma Limited (PPLPHARMA) gains 5% intraday

Piramal Pharma Limited (PPLPHARMA) stock gains 5% intraday, nearing key resistance at ₹176.98. Follow the latest trend in specialty & generic drug manufactur.

Pranab Tyagi at TradeAlone

Published

on

Piramal Pharma Limited PPLPHARMA gains 5% intraday

Piramal Pharma Limited (PPLPHARMA) gained +5% to move higher intraday, reaching ₹176.98 on the NSE on 03 Jul 2026. The stock’s move is driven by technical factors, specifically the shift in trendline status from CONSOLIDATING UP to CONSOLIDATION. This indicates that while the stock is gaining, it has not yet cleared resistance and remains within a consolidation phase. In the healthcare sector, particularly among drug manufacturers, PPLPHARMA’s move appears to be more company-specific rather than a broad sector momentum, given the lack of significant news or filings.

Technical setup — trendlines & DMA

Currently, the 6-month support trendline stands at ₹161.62, which is 8.68% below today’s price, providing a solid floor for the stock. Resistance is set at ₹190.43, which is 7.60% above the current price, indicating room for further upward movement if the stock can break this level. The 50-day moving average (DMA) at ₹169.1 is slightly below the 200-DMA at ₹169.9, suggesting a bearish trend in the short term but indicating potential for recovery if the stock can sustain above these levels. PPLPHARMA is trading in the middle third of its 52-week range, between ₹132.3 and ₹220.8, implying that a significant portion of the potential move is already priced in, but there is still room for growth if positive momentum continues.

6M Trendline — Intraday Snapshot
CONSOLIDATION₹160₹165₹170₹17522 May5 Jun19 Jun3 Jul

Snapshot: ₹176.98 on 2026-07-03 (chart frozen at publication)

Fundamentals & business context

The stock’s fundamental picture shows a mixed bag. With a revenue CAGR of 8.0% over the past five years but no profit CAGR, the market seems to be pricing in potential future earnings rather than current profitability. The company’s -3.7% profit margin and recent quarterly loss signal caution, suggesting that the market may be anticipating a turnaround that has not yet materialized. Institutional ownership at 21.4% indicates that some smart money is betting on the company, but the low dividend yield of 0.08% and negligible PEG ratio due to insufficient growth data raise questions about the immediate income generation and growth prospects. There were no new NSE filings or concalls in the last two days, reinforcing the technical nature of today’s move.

PPLPHARMA
Holdings Analysis
Key strengths & risk signals
61
Overall
43
Fundamental
79
Technical
Risks (1)
Cannot calculate PEG - insufficient growth data.
Strengths (3)
BULLISH TREND! 50-day average (213.3) is above 200-day average (181.8) - positive signal.
STRONG! Trading at 91.8% of 52W range - near yearly highs.
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.

Algorithmic scorecard

The algorithmic scorecard reflects a technically strong but fundamentally weak stock. The overall score of 52 out of 100 highlights this dichotomy. On the positive side, the stock’s bullish sentiment over the last 30 days, with a 5.71x higher average volume on up days compared to down days, points to systematic accumulation. Additionally, the low volatility indicated by a beta of 0.40 suggests that PPLPHARMA is a stable stock with less market risk. On the downside, the company’s low profit margin of -3.7% and the recent quarterly loss are significant risks, indicating thin profits and potential financial instability. The negligible dividend yield of 0.08% also suggests limited income generation for investors, making the stock more of a growth play than an income-focused investment.

Fundamental & Technical AnalysisNSE: PPLPHARMA
66Overall
43Fundamental
89Technical
Growth Quality10 / 30
Revenue CAGR: 7.6% (MODERATE, 8/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin2 / 10
LOW MARGIN! -2.1% profit margin - thin profits.
PEG Valuation0 / 10
Cannot calculate PEG - insufficient growth data.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding14 / 20
MODERATE PUBLIC HOLDING! 24.32% public ownership - balanced ownership structure.
Stability4 / 10
CAREFUL! Company does not have stable profit track. 4 loss-making quarters detected.
Moving Averages12 / 10
BULLISH TREND! 50-day average (213.7) is above 200-day average (182.2) - positive signal.
Price Position8 / 10
STRONG POSITION! Current price (238.9) is above both moving averages.
Trend Pattern20 / 20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance8 / 10
GOOD YEAR! Stock gained 27.5% in the last year.
Volume Sentiment25 / 30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 3,605,550 vs down days: 2,660,317. Ratio: 1.36x
RSI3 / 5
BULLISH! RSI at 66.6 - positive momentum.
52W Range5 / 5
STRONG! Trading at 87.7% of 52W range - near yearly highs.
Momentum3 / 5
MIXED MOMENTUM! Price growth is inconsistent - -2.6% (1 week), 22.9% (1 month), 16.7% (3 months).
Beta / Volatility5 / 5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.

Get all details on PPLPHARMA — P&L, peers, shareholding and more on TradeAlone.

Drug Manufacturers - Specialty and Generic

IPCA Laboratories Limited (NSE: IPCALAB) extends gains, moves up 10% intraday

IPCA Laboratories Limited (NSE: IPCALAB) stock price moves up 10% intraday to ₹1910.0, extending gains and nearing resistance at ₹1970.

jyoti sharma

Published

on

IPCA Laboratories Limited NSE: IPCALAB extends gains

IPCA Laboratories Limited (IPCALAB) extended gains by +10% to ₹1910.0 on the NSE on 17 Aug 2026, as the stock continues to consolidate upwards. This move is driven by the company’s robust financial performance and strategic initiatives, as reflected in its recent corporate announcements and management outlook. IPCALAB operates in the specialty and generic drug manufacturing sector, and today’s move aligns with its strong sector positioning and consistent growth trajectory.

Technical setup — trendlines & DMA

The current trendline structure for IPCALAB shows a 6M support floor at ₹1799.58, which is 5.78% below today’s price. Resistance is approaching at ₹1970, just 3.15% above the current price. The stock is trading at its 50-DMA of ₹1717.2, indicating a key momentum test. With the 50-DMA above the 200-DMA at ₹1542.5, the stock is in a bullish trend. IPCALAB is currently in the upper third of its 52W range, suggesting that a significant portion of its potential upside may already be priced in.

6M Trendline — Intraday Snapshot
CONSOLIDATING UP₹1,500₹1,600₹1,700₹1,800₹1,90022 May19 Jun21 Jul17 Aug

Snapshot: ₹1,910.00 on 2026-08-17 (chart frozen at publication)

Fundamentals & business context

With a PE of 37.9 and profit margins at 11.8%, IPCALAB’s valuation appears stretched relative to its current earnings, though its revenue CAGR of 15.5% and profit CAGR of 34.3% suggest strong growth potential. The 45.2% institutional ownership indicates that smart money has a positive view of the company’s prospects. There was no specific NSE catalyst today, but the stock’s move is consistent with its overall strong fundamental and technical picture.

IPCALAB
Holdings Analysis
Key strengths & risk signals
81
Overall
86
Fundamental
76
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.33% yield - little to no income.
RECOVERY MODE! Current price (1854.1) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -4.3% (1 week), 2.2% (1 month), -1.6% (3 months).
Strengths (4)
UNDERVALUED! PEG of 0.98 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (1936.4) is above 200-day average (1711.9) - positive signal.
GOOD YEAR! Stock gained 31.1% in the last year.
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 318,805 vs down days: 206,284. Ratio: 1.55x

Algorithmic scorecard

The overall algorithmic scorecard for IPCALAB reflects a balanced but slightly technically weak profile. The strongest signals are the revenue and profit CAGRs, which indicate robust growth, and the very low debt levels, showcasing excellent financial health. These factors suggest a company with solid growth prospects and minimal financial risk. However, the negligible dividend yield and weak momentum in the stock’s price growth over the past month are areas of concern. The low dividend yield may disappoint income-seeking investors, while the weak momentum could indicate a potential pullback or consolidation period ahead.

Fundamental & Technical AnalysisNSE: IPCALAB
81Overall
86Fundamental
76Technical
Growth Quality28 / 30
Revenue CAGR: 15.5% (VERY GOOD, 13/15). Profit CAGR: 34.3% (EXCELLENT, 15/15).
Profit Margin5 / 10
DECENT EFFICIENCY! 13.4% profit margin - acceptable profitability.
PEG Valuation10 / 10
UNDERVALUED! PEG of 0.98 indicates stock is cheap relative to growth.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0.33% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.14 - excellent financial health.
Public Holding20 / 20
VERY LESS PUBLIC HOLDING! 8.46% public ownership - strong promoter/institutional control.
Stability10 / 10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Moving Averages12 / 10
BULLISH TREND! 50-day average (1936.4) is above 200-day average (1711.9) - positive signal.
Price Position2 / 10
RECOVERY MODE! Current price (1854.1) above 200-day but below 50-day.
Trend Pattern10 / 20
Current trend: CONSOLIDATING DOWN
52W Performance10 / 10
GOOD YEAR! Stock gained 31.1% in the last year.
Volume Sentiment30 / 30
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 318,805 vs down days: 206,284. Ratio: 1.55x
RSI3 / 5
NEUTRAL! RSI at 42.8 - balanced momentum.
52W Range4 / 5
UPPER HALF! Trading at 72.8% of 52W range - positive territory.
Momentum2 / 5
WEAK MOMENTUM! Limited price growth - -4.3% (1 week), 2.2% (1 month), -1.6% (3 months).
Beta / Volatility3 / 5
MARKET ALIGNED! Beta of 1.00 - moves with the market.

Company outlook

IPCA Laboratories Limited expects overall growth of around 12% to 13% on a consolidated basis for the current financial year, with an EBITDA margin of approximately 22% to 22.3%. The domestic branded business is guided for around 12% growth, with 1% to 2% coming from new product launches and the rest from price increases and volume. However, increased freight costs by around 25% in the fourth quarter are expected to impact profitability until the Iran-U.S. conflict issue is resolved. The company plans to launch around 18 to 20 products annually in the domestic market, 6 to 8 products in the U.S., and 3 to 4 products in each European and other markets. Ipca’s U.S. subsidiary, Pisgah Labs, is constructing a formulation facility expected to be commissioned in the fourth quarter of the current financial year.

Get all details on IPCALAB — P&L, peers, shareholding and more on TradeAlone.

Continue Reading

Drug Manufacturers - Specialty and Generic

IPCA Laboratories Limited (IPCALAB) extends gains by 7% intraday

IPCA Laboratories Limited (IPCALAB) stock moves up 7% intraday to ₹1865.1, extending gains in the Healthcare sector.

Manas shah, Analyst — IT & Software

Published

on

IPCA Laboratories Limited IPCALAB extends gains

IPCA Laboratories Limited (IPCALAB) extended gains by +7% to ₹1865.1 on the NSE today, pushing higher within its consolidating uptrend. The stock is near support at ₹1800, just 3.5% above it, and has not cleared resistance. This move comes after the company informed the Exchange about the Link of Recording for an analysts/institutional investor meet and the voting results from the Annual General Meeting held on August 13, 2026. IPCALAB operates in the specialty and generic drug manufacturing sector, and today’s move appears to be company-specific rather than a sector-wide momentum.

Technical setup — trendlines & DMA

The current trendline structure shows IPCALAB trading above its 6M support trendline at ₹1799.58, which is 3.51% below today’s price. Resistance is at ₹1970.17, with the stock currently 5.63% below this level. The 50-DMA at ₹1717.2 is above the 200-DMA at ₹1542.5, indicating a bullish trend. The stock is trading just above the 50-DMA, suggesting it is either extended or in a recovery phase. Within its 52-week range of ₹1251.6 to ₹1944.9, the stock is in the upper third, implying that a significant portion of the move is already priced in.

6M Trendline — Intraday Snapshot
CONSOLIDATING UP₹1,500₹1,600₹1,700₹1,800₹1,90022 May19 Jun21 Jul17 Aug

Snapshot: ₹1,865.10 on 2026-08-17 (chart frozen at publication)

Fundamentals & business context

With a PE of 37.9 and profit margins at 11.8%, IPCALAB’s valuation appears stretched relative to its current earnings. However, the revenue CAGR of 15.5% and profit CAGR of 34.3% suggest strong growth potential, which may justify the higher PE. The 45.2% institutional ownership indicates that smart money has a positive view of the company’s prospects. There was no specific NSE catalyst today, but the overall growth outlook and strategic plans outlined by management contribute to the stock’s performance.

IPCALAB
Holdings Analysis
Key strengths & risk signals
81
Overall
86
Fundamental
76
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.33% yield - little to no income.
RECOVERY MODE! Current price (1854.1) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -4.3% (1 week), 2.2% (1 month), -1.6% (3 months).
Strengths (4)
UNDERVALUED! PEG of 0.98 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (1936.4) is above 200-day average (1711.9) - positive signal.
GOOD YEAR! Stock gained 31.1% in the last year.
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 318,805 vs down days: 206,284. Ratio: 1.55x

Algorithmic scorecard

The overall algorithmic scorecard of 82 reflects a balanced view, with strong fundamental and technical signals. The two strongest signals are the revenue CAGR of 15.5% and profit CAGR of 34.3%, indicating robust growth. Additionally, the very low debt level with a D/E ratio of 0.16 points to excellent financial health. On the weaker side, the negligible dividend yield of 0.34% offers little income for investors, and the weak momentum with limited price growth over the past month suggests some caution. These factors collectively paint a picture of a company with strong growth potential but also some risks to consider.

Fundamental & Technical AnalysisNSE: IPCALAB
81Overall
86Fundamental
76Technical
Growth Quality28 / 30
Revenue CAGR: 15.5% (VERY GOOD, 13/15). Profit CAGR: 34.3% (EXCELLENT, 15/15).
Profit Margin5 / 10
DECENT EFFICIENCY! 13.4% profit margin - acceptable profitability.
PEG Valuation10 / 10
UNDERVALUED! PEG of 0.98 indicates stock is cheap relative to growth.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0.33% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.14 - excellent financial health.
Public Holding20 / 20
VERY LESS PUBLIC HOLDING! 8.46% public ownership - strong promoter/institutional control.
Stability10 / 10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Moving Averages12 / 10
BULLISH TREND! 50-day average (1936.4) is above 200-day average (1711.9) - positive signal.
Price Position2 / 10
RECOVERY MODE! Current price (1854.1) above 200-day but below 50-day.
Trend Pattern10 / 20
Current trend: CONSOLIDATING DOWN
52W Performance10 / 10
GOOD YEAR! Stock gained 31.1% in the last year.
Volume Sentiment30 / 30
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 318,805 vs down days: 206,284. Ratio: 1.55x
RSI3 / 5
NEUTRAL! RSI at 42.8 - balanced momentum.
52W Range4 / 5
UPPER HALF! Trading at 72.8% of 52W range - positive territory.
Momentum2 / 5
WEAK MOMENTUM! Limited price growth - -4.3% (1 week), 2.2% (1 month), -1.6% (3 months).
Beta / Volatility3 / 5
MARKET ALIGNED! Beta of 1.00 - moves with the market.

Company outlook

IPCA Laboratories Limited expects overall growth of around 12% to 13% on a consolidated basis for the current financial year, with an EBITDA margin of approximately 22% to 22.3%. The domestic branded business is guided for around 12% growth, with 1% to 2% coming from new product launches and the rest from price increases and volume. However, freight costs have increased by around 25% in the fourth quarter, which is expected to impact profitability until the Iran-U.S. conflict issue is resolved. The company plans to launch around 18 to 20 products in the domestic market annually, with 6 to 8 products in the U.S. and 3 to 4 products in each European and other markets. Ipca’s U.S. subsidiary, Pisgah Labs, is constructing a formulation facility expected to be commissioned in the fourth quarter of the current financial year.

Get all details on IPCALAB — P&L, peers, shareholding and more on TradeAlone.

Continue Reading

Drug Manufacturers - Specialty and Generic

Natco Pharma Limited (NATCOPHARM) moves down 6% intraday

Natco Pharma Limited (NATCOPHARM) experiences a 6% intraday decline to ₹892.6, signaling a breakdown in trendline status.

adit chauhan author tradealone

Published

on

Natco Pharma Limited NATCOPHARM breakdown

Natco Pharma Limited (NATCOPHARM) fell -6% to ₹892.6 on the NSE on 14 Aug 2026. The stock’s trendline status shifted from a breakdown to approaching resistance, which likely contributed to the decline. Natco Pharma is a specialty and generic drug manufacturer within the healthcare sector. Today’s move appears to be company-specific, as it does not align with broader sector momentum.

Technical setup — trendlines & DMA

The current 6M trendline structure shows a breakdown, with the stock now trading below the 6M support trendline of ₹914.01 by 2.40%. Resistance is at ₹839.43, which the stock has broken above by 5.96%. The 50-DMA at ₹917.5 is above the 200-DMA at ₹949.9, indicating a bearish trend. However, the stock is currently trading above both moving averages, suggesting some recovery. In the 52W range of ₹789.0–₹1226.8, the stock is in the lower third, implying that much of the downside is already priced in.

6M Trendline — Intraday Snapshot
APPROACHING RESISTANCE₹900₹1,000₹1,10022 May19 Jun20 Jul14 Aug

Snapshot: ₹892.60 on 2026-08-14 (chart frozen at publication)

Fundamentals & business context

With a PE of 12.0, Natco Pharma’s valuation appears reasonable given its strong profit margin of 34.8% and a robust revenue CAGR of 14.8%. The market seems to be pricing in the company’s solid growth trajectory rather than a turnaround. Institutional ownership stands at 12.6%, indicating a cautious but positive view from the smart money. There was no NSE catalyst today that directly influenced the stock’s movement.

NATCOPHARM
Holdings Analysis
Key strengths & risk signals
78
Overall
80
Fundamental
77
Technical
Risks (3)
NEGLIGIBLE DIVIDEND! 0.54% yield - little to no income.
WEAK! Trading at 10.4% of 52W range - near yearly lows.
POSITIVE YEAR! Stock gained 1.7% in the last year.
Strengths (4)
UNDERVALUED! PEG of 0.70 indicates stock is cheap relative to growth.
BREAKOUT! Stock has broken above resistance levels with momentum.
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 944,258 vs down days: 524,960. Ratio: 1.8x
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.

Algorithmic scorecard

The overall algorithmic scorecard reflects a balanced view, with strong fundamental indicators offsetting weaker technical signals. Two of the strongest fundamental signals are the excellent profit margin of 34.8% and the undervalued PEG ratio of 0.47, suggesting the stock is cheap relative to its growth. Additionally, the very low debt level with a D/E ratio of 0.04 indicates excellent financial health. On the weaker side, the negligible dividend yield of 0.72% offers little income for investors, and the bearish trend signaled by the 50-DMA being below the 200-DMA suggests ongoing short-term pressure.

Fundamental & Technical AnalysisNSE: NATCOPHARM
78Overall
80Fundamental
77Technical
Growth Quality26 / 30
Revenue CAGR: 14.5% (GOOD, 11/15). Profit CAGR: 25.6% (EXCELLENT, 15/15).
Profit Margin9 / 10
EXCELLENT EFFICIENCY! 26.8% profit margin - company keeps strong profits.
PEG Valuation10 / 10
UNDERVALUED! PEG of 0.70 indicates stock is cheap relative to growth.
Dividend Yield3 / 10
NEGLIGIBLE DIVIDEND! 0.54% yield - little to no income.
Debt / Equity10 / 10
VERY LOW DEBT! D/E of 0.03 - excellent financial health.
Public Holding14 / 20
MODERATE PUBLIC HOLDING! 24.08% public ownership - balanced ownership structure.
Stability8 / 10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Moving Averages5 / 10
BEARISH TREND! 50-day average (806.0) is below 200-day average (933.2) - negative signal.
Price Position6 / 10
MIXED POSITION! Current price (820.6) above 50-day but below 200-day.
Trend Pattern20 / 20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance4 / 10
POSITIVE YEAR! Stock gained 1.7% in the last year.
Volume Sentiment30 / 30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 944,258 vs down days: 524,960. Ratio: 1.8x
RSI3 / 5
NEUTRAL! RSI at 52.6 - balanced momentum.
52W Range1 / 5
WEAK! Trading at 10.4% of 52W range - near yearly lows.
Momentum3 / 5
MIXED MOMENTUM! Price growth is inconsistent - 1.4% (1 week), 2.5% (1 month), -7.8% (3 months).
Beta / Volatility5 / 5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.

Company outlook

Natco Pharma’s management provided forward guidance expecting revenue of INR3,400-3,500 crores and PAT of INR700-750 crores for FY ’27. They anticipate growth in the Brazil subsidiary revenue to INR55-60 million and expect approvals for cancer pipelines in H2 of FY ’26-’27 with earnings impact in ’27-’28. The company aims to reduce earnings volatility by increasing base revenue contribution to 70% and special products to 25-30%. Additionally, Natco Pharma is exploring 1-2 large acquisitions to diversify its portfolio and build a global footprint. The company plans to invest in R&D with an expected expenditure of 7-9% next year and aims for 15-25% compounded growth in earnings from FY ’28 onwards.

Get all details on NATCOPHARM — P&L, peers, shareholding and more on TradeAlone.

Continue Reading

Trending

Exit mobile version